An interventional study of Direct-to-consumer educational brochure in Inappropriate Dose of Drug Administered, Pain, Chronic and Health Behavior, sponsored by Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-29.
Sponsored by Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal · Not applicable, Interventional, and Health services research
Among 202 studies in Chronic Pain with a site in Canada — 52 open to participants now, 63 under way, 3 of them phase 3. Chronic Pain · Canada.
Among the 202 studies in Chronic Pain with a site in Canada, this one has the largest enrollment of the 162 interventional ones that give a count, is one of 18 that started in 2018, is one of 116 with no phase, and was the 73rd registered.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →52 of the 202 studies in Chronic Pain with a site in Canada are open now. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 65+
University Health Network, Toronto · Sites in Canada
Ages 18–80
University Health Network, Toronto · Sites in Canada
Ages 18–65
University of Manitoba · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 18 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,255 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Median enrollment 49 across the 162 interventional studies, 138 across the 40 observational. Of the 107 that completed or were terminated, 14 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 202 have an industry lead sponsor. The 10 most frequent:
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
16 of the studies in Chronic Pain with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05306899Phase 3University Health Network, TorontoMulti-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | 2027-02-01 |
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT06123715University Health Network, TorontoPerioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty | 2026-12-31 |
| NCT04939623University of CalgaryNovel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal | 2026-12-31 |
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 202 studies in Chronic Pain with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the effectiveness of a government-led population-based opioid intervention on discontinuation of opioid medication in community-dwelling adults with chronic non-cancer pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
Other: Direct-to-consumer educational brochure
This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
Complete cessation of opioids
Provincial prescription insurance claims will be used to measure whether or not opioids are dispensed to community-dwelling adults randomized to either the intervention or control groups between baseline and 6-month follow up. Prescription data contain information on all dispensed prescriptions including drug name, dispensing date, dosage, drug form, the quantity of the drug dispensed, and the license number of the physician who wrote the prescription. Discontinuation of an opioid will be defined as the lack of a prescription claim for at least 60 days.
Time frame: 6 months
Dose reduction or therapeutic switch to an alternate analgesic
The magnitude and direction of dose changes will be assessed for people who do not achieve the primary endpoint of complete cessation. New pharmacy dispensing of a prescription for a lower strength, or supply of a reduced quantity of tablets/patches will be considered in the dose reduction calculation. Where substitution to an alternative opioid occurs, opioid doses will be converted to "oral morphine equivalents" to determine the magnitude and direction of the change. A therapeutic switch will be indicated by a new dispensing for an alternative medication class.
Time frame: 6 months
The proportion of people achieving opioid doses below 90mg oral morphine equivalents.
All opioids will be converted to an oral morphine equivalent dose. The proportion of patients who are prescribed \<90mg of oral morphine equivalent at the end of the 6-month follow up will be compared to baseline.
Time frame: 6 months
Plan to share: Undecided
Ran from Jul 2018 to primary completion in Apr 2019, 9 months.
Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 9 months is below that.
Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal